The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Abstract
Hereditary transthyretin-mediated amyloidosis is a rapidly progressive, heterogeneous disease caused by the accumulation of misfolded transthyretin protein as amyloid fibrils at multiple sites, and is characterized by peripheral sensorimotor neuropathy, autonomic neuropathy and/or cardiomyopathy. Current treatment options have limited efficacy and often do not prevent disease progression. Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein. In Phase II, III and long-term extension studies in patients with hereditary transthyretin-mediated amyloidosis, patisiran has consistently slowed or improved progression of neuropathy. In addition, the Phase III trial demonstrated significant improvements in quality of life measures and indicators of cardiomyopathy. Here, we highlight efficacy and safety data from the patisiran clinical trial programme.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For liver targets, lipid nanoparticles (LNPs) and N-acetylgalactosamine (GalNAc) conjugates are two clinically validated delivery strategies, with multiple regulatory approvals that include Onpattro® (patisiran) 2,3 , Givlaari® (givosiran) 4 , Oxlumo® (lumaisran) 5 , and Leqvio® (inclisiran) [6][7][8] , and numerous additional programs in various stages of clinical development across several thera”
From Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates (2022) · cites this paper as [3]
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,651
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Self-citationTafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington‐Cruz, M., Berk, J. L., Polydefkis, M. J., Dyck, P. J. B., Wang, A. K., Planté‐Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,483
Self-citationNatural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,025
Palladini, G. O., Dispenzieri, A. A., Gertz, M. A., Kumar, S. K., Wechalekar, A. D., Hawkins, P. N., Schönland, S. O., Hegenbart, U., Comenzo, R. L., Kastritis, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7614 · Cited by 978
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Tafamidis for transthyretin familial amyloid polyneuropathy
Coelho, T., Maia, L. F., SILVA, A. C. F. D., Waddington‐Cruz, M., Planté‐Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 812
Self-citation
Research works printed but not linked: 6
- Quarta CC FalkRH SolomonSDet al. The prevalence of cardiac amyloidosis in familial amyloidotic polyneuropathy with predominant neuropathy: the diflunisal trial . XVth International Symposium on Amyloidosis (ISA) Indianapolis IN USA April 27–May 12014 .
- Obici L PerliniS PalladiniGet al. A Phase II study of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis . XIVth International Symposium on Amyloidosis (ISA) Uppsala Sweden ( 2016 ). Poster PA96 .
- Berk J , AdamsD, SuhrOet al. Long-term, open-label clinical experience with patisiran, an investigational RNAi therapeutic for patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy . Orphanet. J. Rare Dis.12 ( Suppl. 1 ), 165 ( 2017 ).
- Solomon SD , AdamsD, KristenAet al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: an analysis of the APOLLO study . Circulation ( 2018 ) ( In press ).
- Suhr OB Gonzalez-DuarteA O’RiordanWet al. Long-term use of patisiran an investigational RNAi therapeutic in patients with hereditary transthyretin-mediated amyloidosis: baseline demographics and interim data form global open label extension study . Presented at: XVIth International Symposium On Amyloidosis (ISA) Kumamoto Japan . 26–29 March 2018 .
- Adams D , Gonzalez-DuarteA, O’RiordanWet al. Patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR amyloidosis with polyneuropathy: results from the Phase 3 APOLLO study . Orphanet. J. Rare Dis.12 ( Suppl. 1 ), 165 ( 2017 ).
Cited by
Sorted by citations
Items 201–269 of 269
He, L., Lin, J., Qin, Z., Xu, Q., Li, H. R., Fu, Y., Xu, R., & Chen, W. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01588-4 · Cited by 4
Delstanche, S., Claeys, K. G., Bleecker, J. D., Remiche, G., Troisfontaines, P., Parys, V. V., & Bondue, A. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2464971 · Cited by 2
Bose, C. K. (2021) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-021-00583-z · Cited by 2
Therapeutic approaches in proteinopathies
Nabi‐Afjadi, M., Dabirmanesh, B., & Uversky, V. N. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.008 · Cited by 2
Lipid‐Based Nanoparticles Using Cell‐Penetrating Peptides
Khalil, I. A., & Harashima, H. (2022) · doi:10.1002/9783527835997.ch17 · Cited by 2
Membrane Environment Sets the Functional pK a of Ionizable LipidsPreprint
Trollmann, M. F. W., Rossetti, P., & Böckmann, R. A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706567 · Cited by 2
Tansou, R., Kubo, T., Nishida, H., Nishimura, Y., Mihara, K., Yanagihara, K., & Seyama, T. (2025) · Biomolecules · doi:10.3390/biom15020293 · Cited by 1
АМИЛОИДОЗ СЕРДЦА (ОБЗОР ЛИТЕРАТУРЫ)
Гафиатулин, М. Р., & Артюх, Л. Ю. (2024) · Медицина: теория и практика · doi:10.56871/mtp.2024.26.38.009 · Cited by 1
Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems
Staller, D. W., Gawargi, F. I., Panigrahi, S. S., Mishra, P. K., & Mahato, R. I. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100065 · Cited by 1
Engineered Salmonella carrying siRNA-PD-1 shrinks orthotopically implanted bladder cancer in rats
Shi, Q., Geng, J., Han, L., Ji, X. Y., Li, J., Mu, Y., Zhao, T., Wang, L., & Jia, H. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2512619 · Cited by 1
Design of a Trigger‐Responsive Photothermal Vesicle‐Based Cargo Delivery Platform
Schramm, A., Conzelmann, N. F., Gelmroth, A.-K., Köberle, J., Schramm, S., Dimova, R., Platzman, I., & Spatz, J. P. (2025) · Small · doi:10.1002/smll.202505852 · Cited by 1
Brain delivery of lipid nanoparticles with shuttle peptides
Martínez-Martínez, N., CARRERA-RODRÍGUEZ, L., Vargas, R., Hernández-Munaín, C., Suñé-Pou, M., & Suñé, C. M. I. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.02.005 · Cited by 1
Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer
George, J., Ma, X., Kadamberi, I. P., Nair, A., Mittal, S., Hashemi, E., Kumar, S., Singh, M., Geethadevi, A., Pradeep, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71468-y · Cited by 1
Qiao, L., Qian, X.-T., Zhang, Y.-G., Peng, X.-F., Liu, Q., Chang, S., Cui, C., (6548), F. Z., Shu-kui, W., & Huang, N. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.178264 · Cited by 1
The landscape and trajectory of global CRISPR therapeutics
Şahin, C., Formica, T. M., Silva, A., Pelle, G. D., Davis, M. C., Andersen, D. G., Çavdar, M., Santos, L., Qiu, L., Olsen, A. L., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103011 · Cited by 1
Perspectives on Genetic Medicine for Cystic Fibrosis
Smirnikhina, S. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220720102556 · Cited by 1
Review of the research and development status of siRNA drugs for gene therapy
Yunfei, P. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/22/20231005 · Cited by 1
Lipid nanoparticles loaded with anticancer bioactives: state of the art
Faria, G. N. F., Bhavsar, D., Munshi, A., & Ramesh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15401-0.00017-8 · Cited by 1
Shier, M. K., Ali, H. H., El‐Wetidy, M. S., Al-Qattan, M. M., & Al‐Fageeh, M. B. (2019) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2019.09.852 · Cited by 1
Computational Approaches for MicroRNA Studies
Mustafa, S. M., Madhavan, M., Sushma, P. S., & Prasad, D. (2022) · Springer eBooks · doi:10.1007/978-981-16-9186-7_10 · Cited by 1
Takács, H., Nagy, V., Rácz, G. A., Kormányos, Á., Polestyuk, B., Schvartz, N., Gyenes, N., Dézsi, L., Radics, B., Iványi, B., et al. (2022) · Cardiologia Hungarica · doi:10.26430/chungarica.2022.52.2.130 · Cited by 1
Dissecting Functional Biological Interactions Using Modular RNA Nanoparticles
Klotz, K. E., Radwan, Y., & Chakrabarti, K. (2022) · Molecules · doi:10.3390/molecules28010228 · Cited by 1
Welcome to the 10th Volume of Neurodegenerative Disease Management
Gautier, L. J. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0032 · Cited by 1
Nahas, H., Saba, S., METLEJ, P., Ribault, C., Vène, É., Lepareur, N., Cammas‐Marion, S., & Loyer, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.26.605135 · Cited by 1
Bench to all Bedsides in Genomics and Precision Medicine
Tcheandjieu, C., Robinson, C., & Natarajan, P. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039202 · Cited by 1
Introducing Volume 9 of Neurodegenerative Disease Management
Dormer, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0051
MiRNA:RBP Interplay as a Key Regulatory Element in Health and Disease
Teneche, M. G., Carbó, N., & Casado, F. J. (2020) · COSMOS · doi:10.1142/s2591722620400098
Engineered genetic tools for directed gene regulation
Ferreira, R. R. (2021) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8703
Gene Therapy: Introduction and Current Status
Khalil, I. A., & Harashima, H. (2021) · Springer eBooks · doi:10.1007/978-3-030-51519-5_114-1
Gene Therapy: Introduction and Current Status
Khalil, I. A., & Harashima, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-84860-6_114
miR-5088-5p inhibitor reduces radiation-induced malignancy by decreasing SlugPreprint
Seok, H. J., Choi, J. Y., Yi, J. M., & Bae, I. H. (2022) · Research Square · doi:10.21203/rs.3.rs-1954909/v1
miRNA: A Prospective Tool for Gene Regulation
Patel, M. A., Jakhesara, S. J., Golaviya, A. V., & KORINGA, P. G. (2022) · Acta Scientific Veterinary Sciences · doi:10.31080/asvs.2022.04.0545
Advancements in the Treatment of Transthyretin Amyloidosis
Wang, R., & Park, C. (2023) · Journal of Student Research · doi:10.47611/jsrhs.v12i1.3883
Role of MicroRNAs in Vascular Remodeling and Repair
Ben‐Aicha, S., Caporali, A., Srivastava, P. K., & Emanueli, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-820719-2.00017-x
Nunes, D. R., Lucchi, D. B. M., Andreata‐Santos, R., Janini, L. M., & Braconi, C. T. (2023) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2023.1176768 · Cited by 2
siRNA-Therapy for Hepatitis B Virus (HBV): A Novel Choice for HBV Treatment
Sarfraz, I. M. (2023) · International Journal of Virology and AIDS · doi:10.23937/2469-567x/1510091
Controlled Delivery of Target-Specific MicroRNA Analogs as a Key to RNAi Therapeutics in Cancer
Grzyb, J., Sławski, J., Collawn, J. F., & Bartoszewski, R. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_201
Kidney transplantation: the recipient
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23571-9.00018-9 · Cited by 1
An optimized polymeric delivery system for piggyBac transposition
Sundaram, D. N. M., C., R., Fu, W., & Uludağ, H. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28665
Generation of liver tissue-resident memory T cells with novel NKT cell agonists and mRNA vaccines
Ganley, M. (2024) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.25792368
Principles of novel cellular and molecular cardiovascular therapeutics
Furtado, M., Ribeiro, M., Martins, S., Carvalho, T., & Carmo‐Fonseca, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822951-4.00042-4
A mini review of Patisiran's efficacy in the management of transthyretin cardiac amyloidosis
Olatunji, G. D., Kokori, E., Ogieuhi, I. J., Ezeano, C., Omoworare, O. T., Olatunji, D., Kanagala, S. G., Elisha, A. A., Aboyeji, D., Oluwatobiloba, A. M., et al. (2024) · Discover Medicine · doi:10.1007/s44337-024-00066-y
Seven, D. (2024) · Farabi Tıp Dergisi · doi:10.59518/farabimedj.1542765
Shuai, Q., Chen, S., Xie, W., Yu, S., & Yan, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5052945
Shuai, Q., Chen, S., Xie, W., Yu, S., & Yan, Y. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5056283
Small Interfering RNA in Kidney Diseases: Promises and Limitations
Losito, A., & Solano, G. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial5010001
Tayeb, A. E. K. A., Chazelas, P., Poinsignon, V., Adams, D., Berthot, C., Cauquil, C. A., Dhaenens, C., Francou, B., Jedraszak, G., Labeyrie, C., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70104
Shuai, Q., Chen, S., Xie, W., Shuisheng, Y., & Yan, Y. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106995
Historical Overview of RNA Therapeutics
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_1
Nanoparticle-Based RNA Interference in Variant Transthyretin Amyloidosis (ATTRv)
Baumeister, C., & Tóthová, N. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00250-1 · Cited by 1
A review of Eplontersen use in hereditary transthyretin amyloidosis
Sama, J. N., Khatri, W., Markus, N., & Dasgupta, N. R. (2025) · Neurodegenerative Disease Management · doi:10.1080/17582024.2025.2554385
mRNA Fate in Human Cells; Degradation and Subcellular Localisation
Jafari, F., Kaur, K., Khan, J. U., Hlow, F. A., Sadraeian, M., Mohkam, M., & Cheng, Y. Y. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70119
Qian, N., Wei, T., Qian, Y., Yang, W., Han, H., Chen, H., & Li, J. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04148-7
Huge, N., Reinkens, T., Buurman, R., Sandbothe, M., Bergmann, A., Wallaschek, H., Vajen, B., Stalke, A., Decker, M., Eilers, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19778235
RNA interference: Basic science to applications in pest management
Palli, S. R., Koo, J., & Moola, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95424-2.00063-7
Nanomaterials for Gene Therapy in Animal Health
Bathla, S. (2026) · Smart nanomaterials technology · doi:10.1007/978-981-95-4542-1_6
Conception d'un logiciel pour la recherche de nouvelles molécules bioactives
Bournez, C. (2019) · theses.fr (ABES) · doi:10.70675/1a4f06f0zdfa4z41efza87az70239c45c50c
Kumari, A. L., & Rath, P. C. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05850-8
RNA therapeutic targeting of recalcitrant and rare cancers
Ishola, A. A., Verusingam, N. D., & Lawal, B. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002373
Ni, S., Kan, K., Zhu, F., Wang, L., Wang, W., & Wu, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728477
Sanftner, L., Beaudry, A., Коваленко, П., Diglio, K., Cyr, W. A., Landrigan, N., Saxena, U. H., Chopda, G. R., Kragh, M., & DUBOIS, B. N. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106190
Drugs Interacting with Nucleic Acids
Silverman, R. B., Xue, F., & Juncosa, J. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15862-9.00009-6
Jawaria, Noor, A., Zarlashat, Y., Khan, M. E. A., Loureiro, E. M., & Dósa, E. (2026) · Life · doi:10.3390/life16081301
van de Schepop, L., Sentí, M. E., Volmerink, N., Wang, F., Mirzahossein, E., Smits, S. M., Seinen, C. W., Stecker, K. E., van Ravensteijn, B. G. P., Vader, P., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7450764
BindingDB Entry 50023055: Repurposing of Agrochemicals as ATTRv Amyloidosis Inhibitors.
BindingDB (2026) · UC San Diego · doi:10.7270/q27d311x
Metadata
- Authors
- Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L.
- Affiliations
- Heidelberg University (DE)
- Department of Neurology Northwestern University Feinberg School of Medicine Chicago IL 60611 USA
- University of Lisbon (PT)
- Mount Sinai Health System (US)
- Cyprus Institute of Neurology and Genetics (CY)
- Policlinico San Matteo Fondazione (IT)
- Venue
- Neurodegenerative Disease Management
- Publisher
- Informa UK Limited
- Published
- 2018-11-27
- Volume
- 9
- Issue
- 1
- Pages
- 5-23
- ISSN
- 1758-2024 (ISSN-L)
- 1758-2032
- OpenAlex
- W2903444830
- Cited by
- 268
- References
- 104
- Citations by year
- 2026: 19 · 2025: 35 · 2024: 49 · 2023: 40 · 2022: 47 · 2021: 32 · 2020: 23 · 2019: 23
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurodegenerative Disease Management (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- patisiran, hereditary transthyretin amyloidosis, prealbumin, RNA interference, amyloidosis, neuropathy, cardiomyopathy, quality of life, drug efficacy, drug safety, clinical trials
- MeSH terms
- RNAi Therapeutics, Clinical Trials as Topic, Humans, Amyloid Neuropathies, Familial, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
